TABLE 1.

IC‐related drugs and their indications.

Target	Drugs	Indications	References
Anti‐PD‐1	Pembrolizumab	Non‐small cell lung cancer; melanoma; head and neck squamous cell cancer; classical Hodgkin lymphoma; primary mediastinal large B‐cell lymphoma; urothelial carcinoma; microsatellite instability‐high or mismatch repair deficient cancer; gastric cancer; esophageal cancer; cervical cancer; hepatocellular carcinoma; Merkel cell carcinoma; renal cell carcinoma; endometrial carcinoma; tumor mutational burden‐high cancer; cutaneous squamous cell carcinoma; triple‐negative breast cancer	27 , 28
	Nivolumab	Melanoma; non‐small cell lung cancer; malignant pleural mesothelioma; renal cell carcinoma; classical Hodgkin lymphoma; squamous cell carcinoma of the head and neck; urothelial carcinoma; microsatellite instability‐high or mismatch repair deficient metastatic colorectal cancer; hepatocellular carcinoma; esophageal cancer; gastric cancer, gastroesophageal junction cancer, esophageal adenocarcinoma	29 , 30 , 31 , 32
	Dostarlimab	Mismatch repair deficient recurrent or advanced endometrial cancer	33 , 34
	Toripalimab	Melanoma; urothelial carcinoma; esophageal cancer; nasopharyngeal carcinoma	35 , 36
	Tislelizumab	Classical Hodgkin lymphoma; urothelial carcinoma; non‐small cell lung cancer; hepatocellular carcinoma; microsatellite instability‐high or mismatch repair deficient cancer; esophageal cancer; nasopharyngeal carcinoma	37 , 38
	Camrelizumab	Classical Hodgkin lymphoma; hepatocellular carcinoma; esophageal cancer; nasopharyngeal carcinoma; non‐small cell lung cancer	39 , 40
	Sintilimab	Classical Hodgkin lymphoma; non‐small cell lung cancer; hepatocellular carcinoma; esophageal squamous cancer; gastric cancer	41 , 42
	Penpulimab	Classical Hodgkin lymphoma	43 , 44
	Zimberelimab	Classical Hodgkin lymphoma	45 , 46
	Serplulimab	Microsatellite instability‐high or mismatch repair deficient cancer; non‐small cell lung cancer	47 , 48 , 49
	Pucotenlimab	Microsatellite instability‐high or mismatch repair deficient cancer; melanoma	50 , 51
Anti‐ PD‐L1	Atezolizumab	Non‐small cell lung cancer; small cell lung cancer; hepatocellular carcinoma; melanoma; alveolar soft part sarcoma	52 , 53
	Durvalumab	Non‐small cell lung cancer; small cell lung cancer; biliary tract cancers; hepatocellular carcinoma	54 , 55
	Envafolimab	microsatellite instability‐high or mismatch repair deficient cancer	56 , 57
	Sugemalimab	Non‐small cell lung cancer	58 , 59 , 60
	Adebrelimab	Small cell lung cancer	61 , 62
Anti‐CTLA4	Ipilimumab	Unresectable or metastatic melanoma; adjuvant treatment of melanoma; advanced renal cell carcinoma; microsatellite instability‐high or mismatch repair deficient metastatic colorectal cancer; hepatocellular carcinoma; metastatic non‐small cell lung cancer; malignant pleural mesothelioma; esophageal cancer	63 , 64
Anti‐CTLA4/PD‐1	Cadonilimab	Cervical cancer	65 , 66